Regeneron Confident In Relationship With Sanofi After Viehbacher’s Departure
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech and French partner remain on track to file PCSK9 inhibitor alirocumab this quarter in U.S. and EU; meanwhile, Eylea continues strong sales growth – but launch in second indication, diabetic macular edema, is slow.